Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AC Immune stock logo
ACIU
AC Immune
$2.14
+2.9%
$1.90
$1.43
$4.26
$214.88M1.62156,452 shs54,870 shs
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
$1.35
-3.9%
$1.19
$0.60
$4.18
$60.40M0.62441,991 shs48,165 shs
23andMe Holding Co. stock logo
ME
23andMe
$0.50
-35.3%
$0.50
$0.53
$9.57
$13.36M1.191.55 million shs29.28 million shs
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
$17.92
-2.3%
$15.50
$2.80
$8.97
$646.16M0.6337,931 shs1.34 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AC Immune stock logo
ACIU
AC Immune
+0.48%0.00%+10.64%+38.67%-40.23%
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-0.71%+8.53%+17.65%+60.15%-48.53%
23andMe Holding Co. stock logo
ME
23andMe
0.00%0.00%0.00%0.00%-94.37%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00%+1.30%+13.42%+25.14%+70.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AC Immune stock logo
ACIU
AC Immune
2.031 of 5 stars
3.51.00.00.02.80.80.6
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
3.4848 of 5 stars
3.55.00.00.00.05.00.6
23andMe Holding Co. stock logo
ME
23andMe
N/AN/AN/AN/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AC Immune stock logo
ACIU
AC Immune
3.00
Buy$12.00460.75% Upside
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
3.00
Buy$8.33519.58% Upside
23andMe Holding Co. stock logo
ME
23andMe
1.00
SellN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SBTX, ME, ACIU, and HOWL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$8.00 ➝ $6.00
5/1/2025
AC Immune stock logo
ACIU
AC Immune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $12.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AC Immune stock logo
ACIU
AC Immune
$28.30M7.59N/AN/A$1.29 per share1.66
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
$1.88M32.10N/AN/A$1.65 per share0.82
23andMe Holding Co. stock logo
ME
23andMe
$208.78M0.06$0.54 per share0.93$2.34 per share0.21
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/A$7.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AC Immune stock logo
ACIU
AC Immune
-$57.83M-$0.58N/AN/AN/A-177.79%-44.60%-22.25%8/5/2025 (Estimated)
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-$70.51M-$1.67N/AN/AN/AN/A-89.37%-54.87%8/14/2025 (Estimated)
23andMe Holding Co. stock logo
ME
23andMe
-$666.70M-$15.45N/AN/A-183.39%-170.07%-62.13%N/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
-$89.48M-$2.42N/AN/AN/A-29.62%-28.20%N/A

Latest SBTX, ME, ACIU, and HOWL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-$0.50N/AN/AN/AN/AN/A
8/5/2025Q2 2025
AC Immune stock logo
ACIU
AC Immune
-$0.18N/AN/AN/A$1.98 millionN/A
5/8/2025Q1 2025
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
-$0.44-$0.40+$0.04-$0.40$0.30 millionN/A
4/30/2025Q1 2025
AC Immune stock logo
ACIU
AC Immune
-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AC Immune stock logo
ACIU
AC Immune
N/AN/AN/AN/AN/A
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
N/AN/AN/AN/AN/A
23andMe Holding Co. stock logo
ME
23andMe
N/AN/AN/AN/AN/A
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AC Immune stock logo
ACIU
AC Immune
N/A
1.53
1.53
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
0.46
8.09
8.09
23andMe Holding Co. stock logo
ME
23andMe
N/A
1.05
0.91
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
N/A
67.87
67.87

Institutional Ownership

CompanyInstitutional Ownership
AC Immune stock logo
ACIU
AC Immune
51.36%
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
64.84%
23andMe Holding Co. stock logo
ME
23andMe
36.10%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
74.89%

Insider Ownership

CompanyInsider Ownership
AC Immune stock logo
ACIU
AC Immune
4.60%
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
23.60%
23andMe Holding Co. stock logo
ME
23andMe
26.32%
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
34.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
AC Immune stock logo
ACIU
AC Immune
140100.41 million95.79 millionOptionable
Werewolf Therapeutics, Inc. stock logo
HOWL
Werewolf Therapeutics
4044.87 million34.28 millionOptionable
23andMe Holding Co. stock logo
ME
23andMe
77026.83 million19.77 millionNot Optionable
Silverback Therapeutics, Inc. stock logo
SBTX
Silverback Therapeutics
8336.06 million23.65 millionNot Optionable

Recent News About These Companies

Meet the Silverback, the Leader of the Troop
10 Fun Facts About Mountain Gorillas
ARS Pharmaceuticals Inc (SPRY)
Wild Isles
A look back at RNA Therapeutics – day one
SPRY ARS Pharmaceuticals, Inc.
FDA accepts ARS Pharma’s NDA for Neffy
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
SBTX Silverback Therapeutics, Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AC Immune stock logo

AC Immune NASDAQ:ACIU

$2.14 +0.06 (+2.88%)
As of 10:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Werewolf Therapeutics stock logo

Werewolf Therapeutics NASDAQ:HOWL

$1.34 -0.06 (-3.93%)
As of 10:52 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

23andMe stock logo

23andMe NASDAQ:ME

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

Silverback Therapeutics stock logo

Silverback Therapeutics NASDAQ:SBTX

$17.92 -0.43 (-2.34%)
As of 07/18/2025

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.